# Interventional Retrospective Case Series of Patients Undergoing Treatment Intervals of More Than Twenty-Four (24) Weeks With Faricimab

## TL;DR

This study shows that extending treatment intervals for faricimab in eye disease patients maintains effectiveness and safety over a year.

## Contribution

The study demonstrates the feasibility of personalized extended dosing of faricimab for retinal diseases.

## Key findings

- Patients showed improved visual acuity with a mean gain of 9.9 letters.
- Anatomical improvement was observed with a 44 μm decrease in macular thickness.
- Extended dosing intervals maintained outcomes over 1 year without increased safety risks.

## Abstract

Purpose: The aim of this study is to evaluate the efficacy and safety of intravitreal faricimab dosing interval at and beyond 24 weeks in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).

Methods: This study is a retrospective case series of eight patients with persistent DME and nAMD who received intravitreal faricimab at and beyond the 24-week (6-month) dosing interval regimen.

Results: The majority of patients experienced an improved mean best-corrected visual acuity (BCVA) of 9.9 letters; congruent anatomical improvement (mean central macular thickness (CMT)) decrease of 44 μm on optical coherence tomography (OCT) is demonstrated at 6 months despite extended faricimab dosing intervals.

Conclusions: Extended intravitreal faricimab dosing intervals at and beyond 24 weeks maintained visual and anatomical outcomes in patients over 1 year. This suggests the feasibility of personalized extended dosing tailored to each patient's disease activity, potentially reducing treatment burden.